|
Mar 6
|
In the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actions
|
|
Mar 5
|
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
|
|
Mar 4
|
Coherus Completes Divestiture of Ophthalmology Franchise
|
|
Jan 25
|
Analysts Are More Bearish On Coherus BioSciences, Inc. (NASDAQ:CHRS) Than They Used To Be
|
|
Jan 12
|
Here’s Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS)
|
|
Dec 24
|
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
|
|
Dec 22
|
Coherus BioSciences Announces New Employment Inducement Grants
|
|
Dec 7
|
Coherus BioSciences Announces CFO Transition Plans
|
|
Dec 6
|
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
|
|
Nov 28
|
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Asso...
|
|
Nov 7
|
Why Coherus Biosciences Stock Dropped Today
|
|
Nov 7
|
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Q3 2023 Coherus BioSciences Inc Earnings Call
|
|
Nov 6
|
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
|
|
Nov 3
|
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
|
|
Nov 3
|
Coherus BioSciences to Participate at Upcoming November Investor Conferences
|
|
Sep 8
|
Coherus Completes Surface Oncology Acquisition
|
|
Sep 8
|
Why Coherus BioSciences Stock Was Plunging This Week
|